Evidence map›Paper›PMID 42399447›Full record

ReviewNPJ precision oncology2026

From tumor regression grading to interpretable endpoints in neoadjuvant oncology.

Cédric Schraepen, Albert Wolthuis, Wentao Tang, André D'Hoore, Giuseppe Floris, Allyson M Peddle, Xavier Sagaert, Sara Verbandt, Thomas McKee, Inti Zlobec and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cédric SchraepenAbdominal Surgery Department, University Hospitals Leuven, Leuven, Belgium. cedric.schraepen@kuleuven.be.
Albert WolthuisAbdominal Surgery Department, University Hospitals Leuven, Leuven, Belgium.
Wentao TangDepartment of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
André D'HooreAbdominal Surgery Department, University Hospitals Leuven, Leuven, Belgium.
Giuseppe FlorisDepartment of Pathology, University Hospitals Leuven, Leuven, Belgium.
Allyson M PeddleLaboratory for Digestive Oncology, KU Leuven, Leuven, Belgium.
Xavier SagaertDepartment of Pathology, University Hospitals Leuven, Leuven, Belgium.
Sara VerbandtLaboratory for Digestive Oncology, KU Leuven, Leuven, Belgium.
Thomas McKeeAurigen SA, Lausanne, Sonic Healthcare Ltd subsidiary, Lausanne, Switzerland.
Inti ZlobecInstitute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
Jianmin XuDepartment of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Sabine TejparLaboratory for Digestive Oncology, KU Leuven, Leuven, Belgium.
Gertjan RasschaertLaboratory for Digestive Oncology, KU Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoadjuvant therapy is expanding rapidly across tumor types, yet efficacy endpoints remain anchored in subjective tumor regression grading systems developed for cytotoxic therapy. We argue that post-treatment histopathology should evolve toward quantitative and biologically interpretable metrics integrating tumor burden, immune contexture, and spatial organization. We outline a validation pathway distinguishing prognostic biomarkers from true surrogate endpoints and propose a tumor- and regimen-aware framework for developing reproducible histologic endpoints in neoadjuvant oncology.

Identifiers

PMID42399447
PMCPMC13696704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.